To better understand the molecular determinants of PARG inhibitor sensitivity, we took a multifaceted approach, analysing (a) model systems engineered to be PARGi sensitive via inhibition of TIMELESS, and (b) intrinsically sensitive ovarian cancer cells. This evidence concerns the gene PARG and ovarian cancer.